That said, one stock that continues to stand out is Johnson & Johnson JNJ. The pharmaceutical giant's stock hit new 52-week highs of nearly $170 on Tuesday, with JNJ now up +16% year to date.
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback